Honokiol Inhibits Epithelial-mesenchymal Transition in Breast Cancer Cells by Targeting Signal Transducer and Activator of Transcription 3/Zeb1/E-cadherin Axis
Overview
Oncology
Authors
Affiliations
Epithelial-mesenchymal transition (EMT), a critical step in the acquisition of metastatic state, is an attractive target for therapeutic interventions directed against tumor metastasis. Honokiol (HNK) is a natural phenolic compound isolated from an extract of seed cones from Magnolia grandiflora. Recent studies from our lab show that HNK impedes breast carcinogenesis. Here, we provide molecular evidence that HNK inhibits EMT in breast cancer cells resulting in significant downregulation of mesenchymal marker proteins and concurrent upregulation of epithelial markers. Experimental EMT induced by exposure to TGFβ and TNFα in spontaneously immortalized nontumorigenic human mammary epithelial cells is also completely reversed by HNK as evidenced by morphological as well as molecular changes. Investigating the downstream mediator(s) that may direct EMT inhibition by HNK, we found functional interactions between HNK, Stat3, and EMT-signaling components. In vitro and in vivo analyses show that HNK inhibits Stat3 activation in breast cancer cells and tumors. Constitutive activation of Stat3 abrogates HNK-mediated activation of epithelial markers whereas inhibition of Stat3 using small molecule inhibitor, Stattic, potentiates HNK-mediated inhibition of EMT markers, invasion and migration of breast cancer cells. Mechanistically, HNK inhibits recruitment of Stat3 on mesenchymal transcription factor Zeb1 promoter resulting in decreased Zeb1 expression and nuclear translocation. We also discover that HNK increases E-cadherin expression via Stat3-mediated release of Zeb1 from E-cadherin promoter. Collectively, this study reports that HNK effectively inhibits EMT in breast cancer cells and provide evidence for a previously unrecognized cross-talk between HNK and Stat3/Zeb1/E-cadherin axis.
Role of STAT3 in cancer cell epithelial‑mesenchymal transition (Review).
Zhang G, Hou S, Li S, Wang Y, Cui W Int J Oncol. 2024; 64(5).
PMID: 38488027 PMC: 11000535. DOI: 10.3892/ijo.2024.5636.
Liu D, Wang L, Li H, Li D, Zhou J, Wang J Molecules. 2024; 29(3).
PMID: 38338418 PMC: 10856273. DOI: 10.3390/molecules29030675.
Targeting the key players of phenotypic plasticity in cancer cells by phytochemicals.
Fakhri S, Moradi S, Abbaszadeh F, Faraji F, Amirian R, Sinha D Cancer Metastasis Rev. 2024; 43(1):261-292.
PMID: 38169011 DOI: 10.1007/s10555-023-10161-8.
Fei Y, Zhang X, Wang X, Sun Y, He J, Liu X J Nat Med. 2023; 78(2):285-295.
PMID: 38082192 DOI: 10.1007/s11418-023-01757-z.
Mikhaevich E, Sorokin D, Scherbakov A Res Pharm Sci. 2023; 18(5):580-591.
PMID: 37842518 PMC: 10568957. DOI: 10.4103/1735-5362.383712.